Home Medicine New target-HMGCR inhibitors for the treatment of primary sclerosing cholangitis: A drug Mendelian randomization study
Article Open Access

New target-HMGCR inhibitors for the treatment of primary sclerosing cholangitis: A drug Mendelian randomization study

  • Jie Zhou , Yixin Xu ORCID logo EMAIL logo , Haitao Wang and Zhilin Liu
Published/Copyright: July 19, 2024

Abstract

Background

No intervention definitively extends transplant-free survival in primary sclerosing cholangitis (PSC). Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), may enhance PSC prognosis, but their efficacy is debated.

Methods

We analyzed HMGCR single-nucleotide polymorphisms from published genome-wide association studies using Mendelian randomization to assess the causal relationship between HMGCR and PSC risk. Effects of HMGCR were compared with proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors, common lipid-lowering drugs, using coronary heart disease risk as a positive control. The inverse-variance weighted (IVW) method was the primary analysis, complemented by the weighted median method. Heterogeneity analysis, examination of horizontal pleiotropy, and leave-one-out sensitivity analysis were conducted for result robustness.

Results

Genetically predicted HMGCR exhibited a pronounced detrimental effect on PSC in both the IVW method (odds ratio [OR] [95%] = 2.43 [1.23–4.78], P = 0.010) and the weighted median method (OR [95%] = 2.36 [1.02–5.45], P = 0.044). However, PCSK9 did not reach statistical significance. Moreover, all analyses passed through heterogeneity analysis, horizontal pleiotropy analysis, and leave-one-out sensitivity analysis.

Conclusion

This study has confirmed a causal relationship between HMGCR and PSC risk, suggesting statins targeting HMGCR could enhance PSC patient outcomes.

1 Introduction

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by injury to the intrahepatic, extrahepatic, or both bile ducts [1]. Although the exact pathogenesis of PSC is unknown, various mechanistic theories have been proposed, involving genetic, immunologic, and environmental factors in the disease’s development [2]. No single drug or treatment has demonstrated a capacity to prolong transplant-free survival in PSC [1]. Despite extensive research on ursodeoxycholic acid (UDCA) as the most commonly used drug, evidence supporting its long-term benefits remains unclear, and its use remains controversial [3,4].

PSC patients are known to have increased lipid levels in serum [5]. Jorgensen et al. demonstrated that hypercholesterolemia is prevalent among patients with PSC, and its occurrence tends to increase with the severity of the disease [6]. Gandelman et al. suggested a disease-specific mechanism for dyslipidemia in PSC based on a case report of a patient with severe dyslipidemia [7]. This case highlights a potential association between the patient’s lipid abnormalities and hepatic impairment in PSC, indicating a disease-specific link. Emerging evidence suggests the potential benefits of statin use in chronic liver diseases [8,9]. A recent meta-analysis indicated that statin use might be linked to a reduced risk of liver failure, death, and portal hypertension [8]. Statins function by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), thereby reducing serum and bile cholesterol levels [10]. Moreover, statins exhibit anti-inflammatory effects, mitigating oxidative stress and inflammation, enhancing nitric oxide synthesis, and improving endothelial function [11]. Additionally, statins have a positive impact on liver inflammation and fibrosis [12]. Currently, only one relevant retrospective study suggests that statins might improve the prognosis of PSC patients [13]. However, despite 70% of PSC patients having concurrent inflammatory bowel disease (IBD) [14], the inclusion of patients with cholangitis and concomitant IBD as PSC in this study has rendered the results less convincing. In summary, the use of statin drugs for treating PSC has not yet gained widespread recognition.

Proprotein convertase subtilis kexin 9 (PCSK9) is a serine protease that plays a crucial role in regulating low-density lipoprotein cholesterol (LDL-C) metabolism, emerging as a key target for cholesterol-lowering therapies [15]. Furthermore, inhibitors of HMGCR and PCSK9 have been extensively employed in the treatment of coronary heart disease (CHD) [16]. Recent discoveries have highlighted that PCSK9 can stimulate the secretion of inflammatory cytokines by monocyte-macrophages through pathways such as TLR4/NF-κB, contributing to inflammation [17]. Additionally, PCSK9 inhibitors have shown therapeutic effects in the autoimmune disease systemic lupus erythematosus [16]. However, the therapeutic role of PCSK9 inhibitors in PSC, also an autoimmune disease, has yet to be explored.

Drug target Mendelian randomization (MR) analysis employs genetic variation simulating the pharmacological inhibition of pharmacogenetic targets as instrumental variables (IVs). Through regression analysis, it can illuminate the effects of long-term drug use and enhance the causal inference regarding the potential impact of these drug gene targets on PSC [15,18]. In this study, we collected recently published genome-wide association study (GWAS) summary-level statistics and investigated the causal relationship between genetically predicted HMGCR and PCSK9 inhibitors and PSC by conducting drug-targeted MR analysis.

2 Materials and methods

2.1 Data sources

The LDL-C levels data for this analysis were sourced from the largest-to-date GWAS, which included participants of European ancestry from the UK Biobank (n = 440,546) [19]. Replication analysis utilized LDL-C data extracted from the most representative GWAS of subjects from the Global Lipids Genetics Consortium (n = 173,082) [20]. The PSC dataset (n = 14,890) was obtained from the International PSC Study Group, as reported by Ji et al. which investigated the relationship between PSC quantity and single-nucleotide polymorphisms (SNPs) [21]. In this study, we utilized PSC as the result of the drug target MR analysis, with CHD serving as a positive control dataset. The GWAS summary data for CHD were sourced from the Coronary Artery Disease Genome-wide Replication and Meta-analysis plus The Coronary Artery Disease Genetics Consortium, which included 184,305 samples [22]. The SNPs included in the above dataset were obtained from the MRC IEU OPENGWAS database (https://gwas.mrcieu.ac.uk/datasets/) (Table 1). This study was based on publicly available summary data and required no ethics approval or participant consent.

Table 1

Details of the genome-wide association studies and datasets used in our analyses

Items ID Population Data sources PMID
LDL-C ieu-b-110 European: 440,546 UK Biobank 32203549
LDL-C ieu-a-300 European: 173,082 GLGC 24097068
CHD ieu-a-7 Mixed: 184,305 CARDIoGRAMplusC4D 26343387
PSC ieu-a-1112 Mixed: 14,890 IPSCSG 27992413

CHD, coronary heart disease; PSC, primary sclerosing cholangitis; GLGC, Global Lipids Genetics Consortium; CARDIoGRAMplusC4D, Coronary ARtery Disease Genome wide Replication and Meta-analysis plus The Coronary Artery Disease Genetics; IPSCSG, International PSC Study Group.

2.2 Selection of IVs

In this study, IVs were selected as SNPs located within ±100 kb of HMGCR or PCSK9 loci and associated with LDL-C levels. IVs with a P-value of less than 5 × 10−8 were chosen to enhance the robustness of IV estimation. To mitigate the impact of strong linkage disequilibrium on the results, a linkage disequilibrium threshold was set (r 2 < 0.3). A total of 19 significant SNPs of HMGCR and 33 SNPs of PCSK9 were identified (Table S1). Pertinent information for each SNP, including the effect allele, effect size (β-value), standard error, and P-value, was extracted from the MR results. Subsequently, we assessed the strength of the IVs by evaluating the proportion of variation explained (R 2) and F-statistics. A threshold of F < 10 was employed to define a “weak IV,” which would be excluded from the study.

2.3 Data analysis

HMGCR and PCSK9 inhibitors are widely employed in treating CHD. Consequently, we utilized GWAS summary data for CHD as a positive control to validate the effectiveness of IVs. Initially, we harmonized the exposure-related drug-targeting IVs with the outcome datasets. We then employed the weighted median and inverse-variance weighted (IVW) methods for analysis, with the IVW method being the most commonly used. A P-value of less than 0.05 was considered indicative of a causal relationship between exposure and outcome.

Heterogeneity was assessed using MR Egger and IVW methods. Cochrane’s Q value was used to evaluate the heterogeneity of the genetic tools, with P > 0.05 suggesting no significant heterogeneity. MR Egger regression equation was applied to assess the horizontal pleiotropy of the genetic tools, and P > 0.05 indicated the absence of horizontal pleiotropy. Sensitivity analysis was conducted again after removing outliers through the MR-PRESSO test.

To ensure our results were not significantly influenced by a particular SNP, we utilized the leave-one-out method, sequentially removing each SNP and comparing the results of the IVW method with all variants. The MR hypothesis requires that SNPs are not directly related to the results (Figure 1). Therefore, the online tool PhenoScanner (http://www.phenoscanner.medschl.cam.ac.uk/) was used to identify traits directly related to the tool variable SNP, excluding those related to CHD and PSC. Data analysis was performed on R version 4.2.3 using MRPRESSO and “TwoSampleMR” packages.

Figure 1 
                  Research overview and design of drug target MR analysis. LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; CHD, coronary heart disease; PSC, primary sclerosing cholangitis; PCSK9 and HMGCR inhibitors are extensively employed to mitigate the risk of CHD. Consequently, we have designated CHD as a positive control. To substantiate the presence of a causal correlation, it is imperative to adhere to the following conditions: †IVs are unrelated to confounding factors, ‡there is a connection between IVs and the exposure factor, and §IVs do not exhibit a direct association with the outcome.
Figure 1

Research overview and design of drug target MR analysis. LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; CHD, coronary heart disease; PSC, primary sclerosing cholangitis; PCSK9 and HMGCR inhibitors are extensively employed to mitigate the risk of CHD. Consequently, we have designated CHD as a positive control. To substantiate the presence of a causal correlation, it is imperative to adhere to the following conditions: IVs are unrelated to confounding factors, there is a connection between IVs and the exposure factor, and §IVs do not exhibit a direct association with the outcome.

  1. Ethical approval: This study was based on publicly available summary data and required no ethics approval or participant consent.

3 Results

3.1 Positive control analysis

As anticipated, HMGCR significantly increased the risk of CHD in both the IVW method (OR [95%] = 1.62 [1.36–1.93], P = 8.29 × 10−8) and weighted median method (OR [95%] = 1.61 [1.27–2.04], P = 7.09 × 10−5) (Figure 2). This effect was similar to that of PCSK9 (IVW: OR [95%] = 2.30 [1.95–2.70], P = 7.20 × 10−24; weighted median: OR [95%] = 2.13 [1.70–2.66], P = 3.54 × 10−11) (Figure 2). Upon testing, these results showed no significant heterogeneity or horizontal pleiotropy (P > 0.05) (Table S2).

Figure 2 
                  The effect of HMGCR and PCSK9 inhibitor on CHD and PSC. nsnp, number of SNPs; OR, odds ratio; CI, confidence interval; PCSK9, proprotein convertase subtilisin/kexin 9; HMGCR, 3-hydroxy-3-methylglutaryl coenzyme A reductase; CHD, coronary heart disease.
Figure 2

The effect of HMGCR and PCSK9 inhibitor on CHD and PSC. nsnp, number of SNPs; OR, odds ratio; CI, confidence interval; PCSK9, proprotein convertase subtilisin/kexin 9; HMGCR, 3-hydroxy-3-methylglutaryl coenzyme A reductase; CHD, coronary heart disease.

A “leave-one-out” sensitivity analysis was performed to investigate whether the causal associations were driven by any single SNP (Figure 3a). The results indicated that stepwise exclusion of each SNP did not significantly alter the model effect estimates or qualitative inferences. Similar results were obtained by repeating the analysis with another GWAS dataset (Tables S3 and S4), and this result demonstrated no significant heterogeneity or horizontal pleiotropy (Table S5).

Figure 3 
                  Sensitivity analysis of HMGCR on CHD and PSC. Leave-one-out analysis of HMGCR on CHD (a), PSC (b). The leave-one-out method is used to evaluate the excessive impact of a single SNP on MR analysis if the comprehensive effect of the remaining SNPs is consistent with the main effect after removing one SNP. The IVs select SNPs that are located within ±100 kb of HMGCR loci and related to LDL-C level. SNP, single nucleotide polymorphisms. HMGCR, 3-hydroxy-3-methylglutaryl coenzyme A reductase. CHD, coronary heart disease.
Figure 3

Sensitivity analysis of HMGCR on CHD and PSC. Leave-one-out analysis of HMGCR on CHD (a), PSC (b). The leave-one-out method is used to evaluate the excessive impact of a single SNP on MR analysis if the comprehensive effect of the remaining SNPs is consistent with the main effect after removing one SNP. The IVs select SNPs that are located within ±100 kb of HMGCR loci and related to LDL-C level. SNP, single nucleotide polymorphisms. HMGCR, 3-hydroxy-3-methylglutaryl coenzyme A reductase. CHD, coronary heart disease.

3.2 The causal relationship between gene‑simulated HMGCR and PCSK9 and PSC

Genetically predicted HMGCR exhibited a pronounced detrimental effect on PSC in both the IVW method (OR [95%] = 2.43 [1.23–4.78], P = 0.010) and weighted median method (OR [95%] = 2.36 [1.02–5.45], P = 0.04) (Figure 2). However, PCSK9 did not reach statistical significance (IVW: P = 0.85; weighted median method: P = 0.90) (Figure 2). The robustness of the results was assessed using Cochrane’s Q and the MR Egger regression equation, both of which showed no significant heterogeneity or horizontal pleiotropy (P > 0.05) (Table S2).

A “leave-one-out” sensitivity analysis was performed to investigate whether the causal associations between HMGCR and PSC were driven by any single SNP. Importantly, both predictive outputs and interpretative conclusions remained robust, irrespective of the omission of any one SNP factor (Figure 3b). Analyses using PhenoScanner indicated that SNPs were primarily associated with blood lipids and body fat content and were not directly related to the outcome variables. Additionally, we used another GWAS dataset for repeated analysis, reaching similar conclusions (Table S4). Furthermore, the results of sensitivity analysis demonstrated no heterogeneity and horizontal pleiotropy in all other outcomes (P > 0.05) (Table S5).

4 Discussion

Extensive research has explored various treatments for PSC, including UDCA [23], immunosuppressive therapy [24], and antibiotics [25], among others. However, no single intervention has definitively proven to significantly extend transplant-free survival in PSC patients [1]. Notably, statins targeting HMGCR show promise in improving the prognosis of individuals with PSC [13]. However, flaws in the inclusion criteria, specifically categorizing patients with both cholangitis and IBD as having PSC, render the conclusions of this study contentious [26]. In a pioneering approach, our study is the first to use two-sample MR analysis with large-scale GWAS datasets, establishing a causal link between HMGCR and PSC. A series of sensitivity analyses supported the findings mentioned above. In brief, our results suggest that HMGCR inhibition could enhance PSC prognosis, providing robust evidence supporting the therapeutic use of statins in PSC treatment.

PSC is commonly associated with cholestasis and abnormal lipid metabolism [6]. Patients with PSC often exhibit elevated lipid levels. In PSC patients with compensated liver disease, LDL-C levels show a positive correlation with the degree of cholestasis, as indicated by liver biochemistries [5,6]. Additionally, research has demonstrated that UDCA not only alleviates cholestasis symptoms but also has a positive impact on total cholesterol and LDL-C levels in patients with cholestasis [27]. This observation suggests a potential pathogenic pathway in PSC related to lipid metabolism [5].

Statins, commonly employed as lipid-lowering agents, function by inhibiting cholesterol production and reducing serum cholesterol levels through the inhibition of HMGCR [28]. However, their clinical efficacy appears to extend beyond LDL-C reduction, a phenomenon recognized as “statin pleiotropy” [29]. Notably, research has unveiled potent anti-inflammatory properties of statins in the context of Staphylococcus aureus alpha-toxin infection [30]. Additionally, statins have demonstrated the ability to significantly decrease CRP levels in hypercholesterolemic patients over an 8-week period, independent of lipid levels [31]. Two meta-analyses have highlighted the role of statins in attenuating disease activity in rheumatoid arthritis (RA) by lowering serum inflammatory markers and improving symptoms [32,33]. A large population-based nested case-control study has further supported the notion that statin use reduces the risk of RA. Concurrently, evidence suggests that statins may modulate the immune system by regulating T-cell signaling, antigen presentation, immune cell migration, and cytokine production [34]. Their potential therapeutic application extends to various autoimmune diseases, including systemic lupus erythematosus [35], multiple sclerosis [36], and graft-versus-host disease [37]. In our study, we established a causal relationship between HMGCR and PSC through MR analysis, demonstrating that statins, as inhibitors of HMGCR, enhance the prognosis of PSC patients. However, the precise mechanism of action remains unclear. It is plausible that statins exert anti-inflammatory effects by reducing oxidative stress and inflammation, diminishing the activation of inflammatory cells [38,39], and improving endothelial function through increased nitric oxide synthesis, restoration of endothelial cell function, and augmentation of endothelial progenitor cells [40,41]. Additionally, prior research suggests that statins positively impact hepatic inflammation, fibrosis, and hepatic vascular tone. Recent studies have also linked statin use to the risk of fibrosis progression and hepatic decompensation in individuals with chronic liver diseases [8].

It must be acknowledged that our study has certain limitations. First, because MR analysis is merely a method to analyze the causal relationship between exposure and outcome, it cannot replace clinical trials in the real world. Additionally, we failed to elucidate the specific mechanism by which HMGCR inhibitors improve the prognosis of PSC patients. Furthermore, due to genetic heterogeneity among various populations, future research should conduct subgroup analyses in diverse populations to obtain a more comprehensive conclusion.

5 Conclusions

This study has established a causal relationship between HMGCR and PSC. The results offer robust evidence supporting the potential enhancement of prognosis in PSC patients through the use of statin drugs targeting HMGCR. It also brings new hope to a large number of PSC patients.

  1. Funding information: This study was funded by the Jiangsu University Medical Education Collaborative Innovation Fund Project (No. JDY2023018) and the Medical Research Project of Jiangsu Health Commission (No. Z2021010).

  2. Author contributions: J. Zhou and Y. Xu designed the study; J. Zhou and Z. Liu extracted data; J. Zhou and H. Wang analyzed and interpreted the data; and J. Zhou wrote the manuscript.

  3. Conflict of interest: The authors declare no competing interests.

  4. Data availability statement: Data are available from the corresponding author upon reasonable request.

References

[1] Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M. Primary sclerosing cholangitis. Lancet. 2018;391(10139):2547–59.10.1016/S0140-6736(18)30300-3Search in Google Scholar PubMed

[2] Sarcognato S, Sacchi D, Grillo F, Cazzagon N, Fabris L, Cadamuro M, et al. Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis. Pathologica. 2021;113(3):170–84.10.32074/1591-951X-245Search in Google Scholar PubMed PubMed Central

[3] Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology. 2005;129(5):1464–72.10.1053/j.gastro.2005.08.017Search in Google Scholar PubMed

[4] Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology. 1992;16(3):707–14.10.1002/hep.1840160315Search in Google Scholar PubMed

[5] Sinakos E, Abbas G, Jorgensen RA, Lindor KD. Serum lipids in primary sclerosing cholangitis. Dig Liver Dis. 2012;44(1):44–8.10.1016/j.dld.2011.07.020Search in Google Scholar PubMed

[6] Jorgensen RA, Lindor KD, Sartin JS, LaRusso NF, Wiesner RH. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol. 1995;20(3):215–9.10.1097/00004836-199504000-00011Search in Google Scholar PubMed

[7] Gandelman G, Aronow WS, Weiss MB. Resolving hyperlipidemia after liver transplantation in a patient with primary sclerosing cholangitis. Am J Ther. 2006;13(2):171–4.10.1097/00045391-200603000-00014Search in Google Scholar PubMed

[8] Kim RG, Loomba R, Prokop LJ, Singh S. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15(10):1521–30.e8.10.1016/j.cgh.2017.04.039Search in Google Scholar PubMed PubMed Central

[9] Chang FM, Wang YP, Lang HC, Tsai CF, Hou MC, Lee FY, et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study. Hepatology. 2017;66(3):896–907.10.1002/hep.29172Search in Google Scholar PubMed

[10] Schierwagen R, Uschner FE, Magdaleno F, Klein S, Trebicka J. Rationale for the use of statins in liver disease. Am J Physiol Gastrointest Liver Physiol. 2017;312(5):G407–12.10.1152/ajpgi.00441.2016Search in Google Scholar PubMed

[11] Zafra C, Abraldes JG, Turnes J, Berzigotti A, Fernández M, Garca-Pagán JC, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology. 2004;126(3):749–55.10.1053/j.gastro.2003.12.007Search in Google Scholar PubMed

[12] Abraldes JG, Villanueva C, Aracil C, Turnes J, Hernandez-Guerra M, Genesca J, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology. 2016;150(5):1160–70.e3.Search in Google Scholar

[13] Stokkeland K, Höijer J, Bottai M, Söderberg-Löfdal K, Bergquist A. Statin use is associated with improved outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2019;17(9):1860–6.e1.10.1016/j.cgh.2018.11.002Search in Google Scholar PubMed

[14] Sabino J, Vieira-Silva S, Machiels K, Joossens M, Falony G, Ballet V, et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut. 2016;65(10):1681–9.10.1136/gutjnl-2015-311004Search in Google Scholar PubMed PubMed Central

[15] Rosoff DB, Bell AS, Jung J, Wagner J, Mavromatis LA, Lohoff FW. Mendelian randomization study of PCSK9 and HMG-CoA reductase inhibition and cognitive function. J Am Coll Cardiol. 2022;80(7):653–62.10.1016/j.jacc.2022.05.041Search in Google Scholar PubMed

[16] Xie W, Li J, Du H, Xia J. Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study. Arthritis Res Ther. 2023;25(1):148.10.1186/s13075-023-03122-7Search in Google Scholar PubMed PubMed Central

[17] Tang ZH, Peng J, Ren Z, Yang J, Li TT, Li TH, et al. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway. Atherosclerosis. 2017;262:113–22.10.1016/j.atherosclerosis.2017.04.023Search in Google Scholar PubMed

[18] Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. Stat Methods Med Res. 2017;26(5):2333–55.10.1177/0962280215597579Search in Google Scholar PubMed PubMed Central

[19] Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis. PLoS Med. 2020;17(3):e1003062.10.1371/journal.pmed.1003062Search in Google Scholar PubMed PubMed Central

[20] Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45(11):1274–83.10.1038/ng.2797Search in Google Scholar PubMed PubMed Central

[21] Ji SG, Juran BD, Mucha S, Folseraas T, Jostins L, Melum E, et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet. 2017;49(2):269–73.10.1038/ng.3745Search in Google Scholar PubMed PubMed Central

[22] Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 2015;47(10):1121–30.10.1038/ng.3396Search in Google Scholar PubMed PubMed Central

[23] Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50(3):808–14.10.1002/hep.23082Search in Google Scholar PubMed PubMed Central

[24] Hommes DW, Erkelens W, Ponsioen C, Stokkers P, Rauws E, van der Spek M, et al. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol. 2008;42(5):522–6.10.1097/MCG.0b013e3181662426Search in Google Scholar PubMed

[25] Färkkilä M, Karvonen AL, Nurmi H, Nuutinen H, Taavitsainen M, Pikkarainen P, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology. 2004;40(6):1379–86.10.1002/hep.20457Search in Google Scholar PubMed

[26] Dubrovsky AMK, Bowlus CL. Statins, fibrates, and other peroxisome proliferator-activated receptor agonists for the treatment of cholestatic liver diseases. Gastroenterol Hepatol (N Y). 2020;16(1):31–8.Search in Google Scholar

[27] Balan V, Dickson ER, Jorgensen RA, Lindor KD. Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis. Mayo Clin Proc. 1994;69(10):923–9.10.1016/S0025-6196(12)61815-1Search in Google Scholar PubMed

[28] Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988;319(1):24–33.10.1056/NEJM198807073190105Search in Google Scholar PubMed

[29] Yu D, Liao JK. Emerging views of statin pleiotropy and cholesterol lowering. Cardiovasc Res. 2022;118(2):413–23.10.1093/cvr/cvab032Search in Google Scholar PubMed PubMed Central

[30] Pruefer D, Makowski J, Schnell M, Buerke U, Dahm M, Oelert H, et al. Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation. 2002;106(16):2104–10.10.1161/01.CIR.0000034048.38910.91Search in Google Scholar PubMed

[31] Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 2001;103(9):1191–3.10.1161/01.CIR.103.9.1191Search in Google Scholar PubMed

[32] Lv S, Liu Y, Zou Z, Li F, Zhao S, Shi R, et al. The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis. Clin Exp Rheumatol. 2015;33(1):69–76.Search in Google Scholar

[33] Li GM, Zhao J, Li B, Zhang XF, Ma JX, Ma XL, et al. The anti-inflammatory effects of statins on patients with rheumatoid arthritis: A systemic review and meta-analysis of 15 randomized controlled trials. Autoimmun Rev. 2018;17(3):215–25.10.1016/j.autrev.2017.10.013Search in Google Scholar PubMed

[34] Hechinger AK, Maas K, Dürr C, Leonhardt F, Prinz G, Marks R, et al. Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cells. Haematologica. 2013;98(1):31–40.10.3324/haematol.2012.065789Search in Google Scholar PubMed PubMed Central

[35] Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatol (Oxf). 2007;46(10):1560–5.10.1093/rheumatology/kem186Search in Google Scholar PubMed

[36] Chan D, Binks S, Nicholas JM, Frost C, Cardoso MJ, Ourselin S, et al. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. Lancet Neurol. 2017;16(8):591–600.10.1016/S1474-4422(17)30113-8Search in Google Scholar PubMed PubMed Central

[37] Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, et al. Recipient immune modulation with atorvastatin for acute graft-versus-host disease prophylaxis after allogeneic transplantation. Biol Blood Marrow Transpl. 2017;23(8):1295–302.10.1016/j.bbmt.2017.04.009Search in Google Scholar PubMed

[38] Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol. 2001;77(2–3):247–53.10.1016/S0167-5273(00)00439-3Search in Google Scholar PubMed

[39] Albert MA, Staggers J, Chew P, Ridker PM. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design. Am Heart J. 2001;141(6):893–8.10.1067/mhj.2001.115297Search in Google Scholar PubMed

[40] McGirt MJ, Lynch JR, Parra A, Sheng H, Pearlstein RD, Laskowitz DT, et al. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke. 2002;33(12):2950–6.10.1161/01.STR.0000038986.68044.39Search in Google Scholar

[41] Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, et al. HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. J Clin Invest. 2001;108(3):399–405.10.1172/JCI13131Search in Google Scholar PubMed PubMed Central

Received: 2024-01-23
Revised: 2024-05-23
Accepted: 2024-06-14
Published Online: 2024-07-19

© 2024 the author(s), published by De Gruyter

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Research Articles
  2. EDNRB inhibits the growth and migration of prostate cancer cells by activating the cGMP-PKG pathway
  3. STK11 (LKB1) mutation suppresses ferroptosis in lung adenocarcinoma by facilitating monounsaturated fatty acid synthesis
  4. Association of SOX6 gene polymorphisms with Kashin-Beck disease risk in the Chinese Han population
  5. The pyroptosis-related signature predicts prognosis and influences the tumor immune microenvironment in dedifferentiated liposarcoma
  6. METTL3 attenuates ferroptosis sensitivity in lung cancer via modulating TFRC
  7. Identification and validation of molecular subtypes and prognostic signature for stage I and stage II gastric cancer based on neutrophil extracellular traps
  8. Novel lumbar plexus block versus femoral nerve block for analgesia and motor recovery after total knee arthroplasty
  9. Correlation between ABCB1 and OLIG2 polymorphisms and the severity and prognosis of patients with cerebral infarction
  10. Study on the radiotherapy effect and serum neutral granulocyte lymphocyte ratio and inflammatory factor expression of nasopharyngeal carcinoma
  11. Transcriptome analysis of effects of Tecrl deficiency on cardiometabolic and calcium regulation in cardiac tissue
  12. Aflatoxin B1 induces infertility, fetal deformities, and potential therapies
  13. Serum levels of HMW adiponectin and its receptors are associated with cytokine levels and clinical characteristics in chronic obstructive pulmonary disease
  14. METTL3-mediated methylation of CYP2C19 mRNA may aggravate clopidogrel resistance in ischemic stroke patients
  15. Understand how machine learning impact lung cancer research from 2010 to 2021: A bibliometric analysis
  16. Pressure ulcers in German hospitals: Analysis of reimbursement and length of stay
  17. Metformin plus L-carnitine enhances brown/beige adipose tissue activity via Nrf2/HO-1 signaling to reduce lipid accumulation and inflammation in murine obesity
  18. Downregulation of carbonic anhydrase IX expression in mouse xenograft nasopharyngeal carcinoma model via doxorubicin nanobubble combined with ultrasound
  19. Feasibility of 3-dimensional printed models in simulated training and teaching of transcatheter aortic valve replacement
  20. miR-335-3p improves type II diabetes mellitus by IGF-1 regulating macrophage polarization
  21. The analyses of human MCPH1 DNA repair machinery and genetic variations
  22. Activation of Piezo1 increases the sensitivity of breast cancer to hyperthermia therapy
  23. Comprehensive analysis based on the disulfidptosis-related genes identifies hub genes and immune infiltration for pancreatic adenocarcinoma
  24. Changes of serum CA125 and PGE2 before and after high-intensity focused ultrasound combined with GnRH-a in treatment of patients with adenomyosis
  25. The clinical value of the hepatic venous pressure gradient in patients undergoing hepatic resection for hepatocellular carcinoma with or without liver cirrhosis
  26. Development and validation of a novel model to predict pulmonary embolism in cardiology suspected patients: A 10-year retrospective analysis
  27. Downregulation of lncRNA XLOC_032768 in diabetic patients predicts the occurrence of diabetic nephropathy
  28. Circ_0051428 targeting miR-885-3p/MMP2 axis enhances the malignancy of cervical cancer
  29. Effectiveness of ginkgo diterpene lactone meglumine on cognitive function in patients with acute ischemic stroke
  30. The construction of a novel prognostic prediction model for glioma based on GWAS-identified prognostic-related risk loci
  31. Evaluating the impact of childhood BMI on the risk of coronavirus disease 2019: A Mendelian randomization study
  32. Lactate dehydrogenase to albumin ratio is associated with in-hospital mortality in patients with acute heart failure: Data from the MIMIC-III database
  33. CD36-mediated podocyte lipotoxicity promotes foot process effacement
  34. Efficacy of etonogestrel subcutaneous implants versus the levonorgestrel-releasing intrauterine system in the conservative treatment of adenomyosis
  35. FLRT2 mediates chondrogenesis of nasal septal cartilage and mandibular condyle cartilage
  36. Challenges in treating primary immune thrombocytopenia patients undergoing COVID-19 vaccination: A retrospective study
  37. Let-7 family regulates HaCaT cell proliferation and apoptosis via the ΔNp63/PI3K/AKT pathway
  38. Phospholipid transfer protein ameliorates sepsis-induced cardiac dysfunction through NLRP3 inflammasome inhibition
  39. Postoperative cognitive dysfunction in elderly patients with colorectal cancer: A randomized controlled study comparing goal-directed and conventional fluid therapy
  40. Long-pulsed ultrasound-mediated microbubble thrombolysis in a rat model of microvascular obstruction
  41. High SEC61A1 expression predicts poor outcome of acute myeloid leukemia
  42. Comparison of polymerase chain reaction and next-generation sequencing with conventional urine culture for the diagnosis of urinary tract infections: A meta-analysis
  43. Secreted frizzled-related protein 5 protects against renal fibrosis by inhibiting Wnt/β-catenin pathway
  44. Pan-cancer and single-cell analysis of actin cytoskeleton genes related to disulfidptosis
  45. Overexpression of miR-532-5p restrains oxidative stress response of chondrocytes in nontraumatic osteonecrosis of the femoral head by inhibiting ABL1
  46. Autologous liver transplantation for unresectable hepatobiliary malignancies in enhanced recovery after surgery model
  47. Clinical analysis of incomplete rupture of the uterus secondary to previous cesarean section
  48. Abnormal sleep duration is associated with sarcopenia in older Chinese people: A large retrospective cross-sectional study
  49. No genetic causality between obesity and benign paroxysmal vertigo: A two-sample Mendelian randomization study
  50. Identification and validation of autophagy-related genes in SSc
  51. Long non-coding RNA SRA1 suppresses radiotherapy resistance in esophageal squamous cell carcinoma by modulating glycolytic reprogramming
  52. Evaluation of quality of life in patients with schizophrenia: An inpatient social welfare institution-based cross-sectional study
  53. The possible role of oxidative stress marker glutathione in the assessment of cognitive impairment in multiple sclerosis
  54. Compilation of a self-management assessment scale for postoperative patients with aortic dissection
  55. Left atrial appendage closure in conjunction with radiofrequency ablation: Effects on left atrial functioning in patients with paroxysmal atrial fibrillation
  56. Effect of anterior femoral cortical notch grade on postoperative function and complications during TKA surgery: A multicenter, retrospective study
  57. Clinical characteristics and assessment of risk factors in patients with influenza A-induced severe pneumonia after the prevalence of SARS-CoV-2
  58. Analgesia nociception index is an indicator of laparoscopic trocar insertion-induced transient nociceptive stimuli
  59. High STAT4 expression correlates with poor prognosis in acute myeloid leukemia and facilitates disease progression by upregulating VEGFA expression
  60. Factors influencing cardiovascular system-related post-COVID-19 sequelae: A single-center cohort study
  61. HOXD10 regulates intestinal permeability and inhibits inflammation of dextran sulfate sodium-induced ulcerative colitis through the inactivation of the Rho/ROCK/MMPs axis
  62. Mesenchymal stem cell-derived exosomal miR-26a induces ferroptosis, suppresses hepatic stellate cell activation, and ameliorates liver fibrosis by modulating SLC7A11
  63. Endovascular thrombectomy versus intravenous thrombolysis for primary distal, medium vessel occlusion in acute ischemic stroke
  64. ANO6 (TMEM16F) inhibits gastrointestinal stromal tumor growth and induces ferroptosis
  65. Prognostic value of EIF5A2 in solid tumors: A meta-analysis and bioinformatics analysis
  66. The role of enhanced expression of Cx43 in patients with ulcerative colitis
  67. Choosing a COVID-19 vaccination site might be driven by anxiety and body vigilance
  68. Role of ICAM-1 in triple-negative breast cancer
  69. Cost-effectiveness of ambroxol in the treatment of Gaucher disease type 2
  70. HLA-DRB5 promotes immune thrombocytopenia via activating CD8+ T cells
  71. Efficacy and factors of myofascial release therapy combined with electrical and magnetic stimulation in the treatment of chronic pelvic pain syndrome
  72. Efficacy of tacrolimus monotherapy in primary membranous nephropathy
  73. Mechanisms of Tripterygium wilfordii Hook F on treating rheumatoid arthritis explored by network pharmacology analysis and molecular docking
  74. FBXO45 levels regulated ferroptosis renal tubular epithelial cells in a model of diabetic nephropathy by PLK1
  75. Optimizing anesthesia strategies to NSCLC patients in VATS procedures: Insights from drug requirements and patient recovery patterns
  76. Alpha-lipoic acid upregulates the PPARγ/NRF2/GPX4 signal pathway to inhibit ferroptosis in the pathogenesis of unexplained recurrent pregnancy loss
  77. Correlation between fat-soluble vitamin levels and inflammatory factors in paediatric community-acquired pneumonia: A prospective study
  78. CD1d affects the proliferation, migration, and apoptosis of human papillary thyroid carcinoma TPC-1 cells via regulating MAPK/NF-κB signaling pathway
  79. miR-let-7a inhibits sympathetic nerve remodeling after myocardial infarction by downregulating the expression of nerve growth factor
  80. Immune response analysis of solid organ transplantation recipients inoculated with inactivated COVID-19 vaccine: A retrospective analysis
  81. The H2Valdien derivatives regulate the epithelial–mesenchymal transition of hepatoma carcinoma cells through the Hedgehog signaling pathway
  82. Clinical efficacy of dexamethasone combined with isoniazid in the treatment of tuberculous meningitis and its effect on peripheral blood T cell subsets
  83. Comparison of short-segment and long-segment fixation in treatment of degenerative scoliosis and analysis of factors associated with adjacent spondylolisthesis
  84. Lycopene inhibits pyroptosis of endothelial progenitor cells induced by ox-LDL through the AMPK/mTOR/NLRP3 pathway
  85. Methylation regulation for FUNDC1 stability in childhood leukemia was up-regulated and facilitates metastasis and reduces ferroptosis of leukemia through mitochondrial damage by FBXL2
  86. Correlation of single-fiber electromyography studies and functional status in patients with amyotrophic lateral sclerosis
  87. Risk factors of postoperative airway obstruction complications in children with oral floor mass
  88. Expression levels and clinical significance of serum miR-19a/CCL20 in patients with acute cerebral infarction
  89. Physical activity and mental health trends in Korean adolescents: Analyzing the impact of the COVID-19 pandemic from 2018 to 2022
  90. Evaluating anemia in HIV-infected patients using chest CT
  91. Ponticulus posticus and skeletal malocclusion: A pilot study in a Southern Italian pre-orthodontic court
  92. Causal association of circulating immune cells and lymphoma: A Mendelian randomization study
  93. Assessment of the renal function and fibrosis indexes of conventional western medicine with Chinese medicine for dredging collaterals on treating renal fibrosis: A systematic review and meta-analysis
  94. Comprehensive landscape of integrator complex subunits and their association with prognosis and tumor microenvironment in gastric cancer
  95. New target-HMGCR inhibitors for the treatment of primary sclerosing cholangitis: A drug Mendelian randomization study
  96. Population pharmacokinetics of meropenem in critically ill patients
  97. Comparison of the ability of newly inflammatory markers to predict complicated appendicitis
  98. Comparative morphology of the cruciate ligaments: A radiological study
  99. Immune landscape of hepatocellular carcinoma: The central role of TP53-inducible glycolysis and apoptosis regulator
  100. Serum SIRT3 levels in epilepsy patients and its association with clinical outcomes and severity: A prospective observational study
  101. SHP-1 mediates cigarette smoke extract-induced epithelial–mesenchymal transformation and inflammation in 16HBE cells
  102. Acute hyper-hypoxia accelerates the development of depression in mice via the IL-6/PGC1α/MFN2 signaling pathway
  103. The GJB3 correlates with the prognosis, immune cell infiltration, and therapeutic responses in lung adenocarcinoma
  104. Physical fitness and blood parameters outcomes of breast cancer survivor in a low-intensity circuit resistance exercise program
  105. Exploring anesthetic-induced gene expression changes and immune cell dynamics in atrial tissue post-coronary artery bypass graft surgery
  106. Empagliflozin improves aortic injury in obese mice by regulating fatty acid metabolism
  107. Analysis of the risk factors of the radiation-induced encephalopathy in nasopharyngeal carcinoma: A retrospective cohort study
  108. Reproductive outcomes in women with BRCA 1/2 germline mutations: A retrospective observational study and literature review
  109. Evaluation of upper airway ultrasonographic measurements in predicting difficult intubation: A cross-section of the Turkish population
  110. Prognostic and diagnostic value of circulating IGFBP2 in pancreatic cancer
  111. Postural stability after operative reconstruction of the AFTL in chronic ankle instability comparing three different surgical techniques
  112. Research trends related to emergence agitation in the post-anaesthesia care unit from 2001 to 2023: A bibliometric analysis
  113. Frequency and clinicopathological correlation of gastrointestinal polyps: A six-year single center experience
  114. ACSL4 mediates inflammatory bowel disease and contributes to LPS-induced intestinal epithelial cell dysfunction by activating ferroptosis and inflammation
  115. Affibody-based molecular probe 99mTc-(HE)3ZHER2:V2 for non-invasive HER2 detection in ovarian and breast cancer xenografts
  116. Effectiveness of nutritional support for clinical outcomes in gastric cancer patients: A meta-analysis of randomized controlled trials
  117. The relationship between IFN-γ, IL-10, IL-6 cytokines, and severity of the condition with serum zinc and Fe in children infected with Mycoplasma pneumoniae
  118. Paraquat disrupts the blood–brain barrier by increasing IL-6 expression and oxidative stress through the activation of PI3K/AKT signaling pathway
  119. Sleep quality associate with the increased prevalence of cognitive impairment in coronary artery disease patients: A retrospective case–control study
  120. Dioscin protects against chronic prostatitis through the TLR4/NF-κB pathway
  121. Association of polymorphisms in FBN1, MYH11, and TGF-β signaling-related genes with susceptibility of sporadic thoracic aortic aneurysm and dissection in the Zhejiang Han population
  122. Application value of multi-parameter magnetic resonance image-transrectal ultrasound cognitive fusion in prostate biopsy
  123. Laboratory variables‐based artificial neural network models for predicting fatty liver disease: A retrospective study
  124. Decreased BIRC5-206 promotes epithelial–mesenchymal transition in nasopharyngeal carcinoma through sponging miR-145-5p
  125. Sepsis induces the cardiomyocyte apoptosis and cardiac dysfunction through activation of YAP1/Serpine1/caspase-3 pathway
  126. Assessment of iron metabolism and iron deficiency in incident patients on incident continuous ambulatory peritoneal dialysis
  127. Tibial periosteum flap combined with autologous bone grafting in the treatment of Gustilo-IIIB/IIIC open tibial fractures
  128. The application of intravenous general anesthesia under nasopharyngeal airway assisted ventilation undergoing ureteroscopic holmium laser lithotripsy: A prospective, single-center, controlled trial
  129. Long intergenic noncoding RNA for IGF2BP2 stability suppresses gastric cancer cell apoptosis by inhibiting the maturation of microRNA-34a
  130. Role of FOXM1 and AURKB in regulating keratinocyte function in psoriasis
  131. Parental control attitudes over their pre-school children’s diet
  132. The role of auto-HSCT in extranodal natural killer/T cell lymphoma
  133. Significance of negative cervical cytology and positive HPV in the diagnosis of cervical lesions by colposcopy
  134. Echinacoside inhibits PASMCs calcium overload to prevent hypoxic pulmonary artery remodeling by regulating TRPC1/4/6 and calmodulin
  135. ADAR1 plays a protective role in proximal tubular cells under high glucose conditions by attenuating the PI3K/AKT/mTOR signaling pathway
  136. The risk of cancer among insulin glargine users in Lithuania: A retrospective population-based study
  137. The unusual location of primary hydatid cyst: A case series study
  138. Intraoperative changes in electrophysiological monitoring can be used to predict clinical outcomes in patients with spinal cavernous malformation
  139. Obesity and risk of placenta accreta spectrum: A meta-analysis
  140. Shikonin alleviates asthma phenotypes in mice via an airway epithelial STAT3-dependent mechanism
  141. NSUN6 and HTR7 disturbed the stability of carotid atherosclerotic plaques by regulating the immune responses of macrophages
  142. The effect of COVID-19 lockdown on admission rates in Maternity Hospital
  143. Temporal muscle thickness is not a prognostic predictor in patients with high-grade glioma, an experience at two centers in China
  144. Luteolin alleviates cerebral ischemia/reperfusion injury by regulating cell pyroptosis
  145. Therapeutic role of respiratory exercise in patients with tuberculous pleurisy
  146. Effects of CFTR-ENaC on spinal cord edema after spinal cord injury
  147. Irisin-regulated lncRNAs and their potential regulatory functions in chondrogenic differentiation of human mesenchymal stem cells
  148. DMD mutations in pediatric patients with phenotypes of Duchenne/Becker muscular dystrophy
  149. Combination of C-reactive protein and fibrinogen-to-albumin ratio as a novel predictor of all-cause mortality in heart failure patients
  150. Significant role and the underly mechanism of cullin-1 in chronic obstructive pulmonary disease
  151. Ferroptosis-related prognostic model of mantle cell lymphoma
  152. Observation of choking reaction and other related indexes in elderly painless fiberoptic bronchoscopy with transnasal high-flow humidification oxygen therapy
  153. A bibliometric analysis of Prader-Willi syndrome from 2002 to 2022
  154. The causal effects of childhood sunburn occasions on melanoma: A univariable and multivariable Mendelian randomization study
  155. Oxidative stress regulates glycogen synthase kinase-3 in lymphocytes of diabetes mellitus patients complicated with cerebral infarction
  156. Role of COX6C and NDUFB3 in septic shock and stroke
  157. Trends in disease burden of type 2 diabetes, stroke, and hypertensive heart disease attributable to high BMI in China: 1990–2019
  158. Purinergic P2X7 receptor mediates hyperoxia-induced injury in pulmonary microvascular endothelial cells via NLRP3-mediated pyroptotic pathway
  159. Investigating the role of oviductal mucosa–endometrial co-culture in modulating factors relevant to embryo implantation
  160. Analgesic effect of external oblique intercostal block in laparoscopic cholecystectomy: A retrospective study
  161. Elevated serum miR-142-5p correlates with ischemic lesions and both NSE and S100β in ischemic stroke patients
  162. Correlation between the mechanism of arteriopathy in IgA nephropathy and blood stasis syndrome: A cohort study
  163. Risk factors for progressive kyphosis after percutaneous kyphoplasty in osteoporotic vertebral compression fracture
  164. Predictive role of neuron-specific enolase and S100-β in early neurological deterioration and unfavorable prognosis in patients with ischemic stroke
  165. The potential risk factors of postoperative cognitive dysfunction for endovascular therapy in acute ischemic stroke with general anesthesia
  166. Fluoxetine inhibited RANKL-induced osteoclastic differentiation in vitro
  167. Detection of serum FOXM1 and IGF2 in patients with ARDS and their correlation with disease and prognosis
  168. Rhein promotes skin wound healing by activating the PI3K/AKT signaling pathway
  169. Differences in mortality risk by levels of physical activity among persons with disabilities in South Korea
  170. Review Articles
  171. Cutaneous signs of selected cardiovascular disorders: A narrative review
  172. XRCC1 and hOGG1 polymorphisms and endometrial carcinoma: A meta-analysis
  173. A narrative review on adverse drug reactions of COVID-19 treatments on the kidney
  174. Emerging role and function of SPDL1 in human health and diseases
  175. Adverse reactions of piperacillin: A literature review of case reports
  176. Molecular mechanism and intervention measures of microvascular complications in diabetes
  177. Regulation of mesenchymal stem cell differentiation by autophagy
  178. Molecular landscape of borderline ovarian tumours: A systematic review
  179. Advances in synthetic lethality modalities for glioblastoma multiforme
  180. Investigating hormesis, aging, and neurodegeneration: From bench to clinics
  181. Frankincense: A neuronutrient to approach Parkinson’s disease treatment
  182. Sox9: A potential regulator of cancer stem cells in osteosarcoma
  183. Early detection of cardiovascular risk markers through non-invasive ultrasound methodologies in periodontitis patients
  184. Advanced neuroimaging and criminal interrogation in lie detection
  185. Maternal factors for neural tube defects in offspring: An umbrella review
  186. The chemoprotective hormetic effects of rosmarinic acid
  187. CBD’s potential impact on Parkinson’s disease: An updated overview
  188. Progress in cytokine research for ARDS: A comprehensive review
  189. Utilizing reactive oxygen species-scavenging nanoparticles for targeting oxidative stress in the treatment of ischemic stroke: A review
  190. NRXN1-related disorders, attempt to better define clinical assessment
  191. Lidocaine infusion for the treatment of complex regional pain syndrome: Case series and literature review
  192. Trends and future directions of autophagy in osteosarcoma: A bibliometric analysis
  193. Iron in ventricular remodeling and aneurysms post-myocardial infarction
  194. Case Reports
  195. Sirolimus potentiated angioedema: A case report and review of the literature
  196. Identification of mixed anaerobic infections after inguinal hernia repair based on metagenomic next-generation sequencing: A case report
  197. Successful treatment with bortezomib in combination with dexamethasone in a middle-aged male with idiopathic multicentric Castleman’s disease: A case report
  198. Complete heart block associated with hepatitis A infection in a female child with fatal outcome
  199. Elevation of D-dimer in eosinophilic gastrointestinal diseases in the absence of venous thrombosis: A case series and literature review
  200. Four years of natural progressive course: A rare case report of juvenile Xp11.2 translocations renal cell carcinoma with TFE3 gene fusion
  201. Advancing prenatal diagnosis: Echocardiographic detection of Scimitar syndrome in China – A case series
  202. Outcomes and complications of hemodialysis in patients with renal cancer following bilateral nephrectomy
  203. Anti-HMGCR myopathy mimicking facioscapulohumeral muscular dystrophy
  204. Recurrent opportunistic infections in a HIV-negative patient with combined C6 and NFKB1 mutations: A case report, pedigree analysis, and literature review
  205. Letter to the Editor
  206. Letter to the Editor: Total parenteral nutrition-induced Wernicke’s encephalopathy after oncologic gastrointestinal surgery
  207. Erratum
  208. Erratum to “Bladder-embedded ectopic intrauterine device with calculus”
  209. Retraction
  210. Retraction of “XRCC1 and hOGG1 polymorphisms and endometrial carcinoma: A meta-analysis”
  211. Corrigendum
  212. Corrigendum to “Investigating hormesis, aging, and neurodegeneration: From bench to clinics”
  213. Corrigendum to “Frankincense: A neuronutrient to approach Parkinson’s disease treatment”
  214. Special Issue The evolving saga of RNAs from bench to bedside - Part II
  215. Machine-learning-based prediction of a diagnostic model using autophagy-related genes based on RNA sequencing for patients with papillary thyroid carcinoma
  216. Unlocking the future of hepatocellular carcinoma treatment: A comprehensive analysis of disulfidptosis-related lncRNAs for prognosis and drug screening
  217. Elevated mRNA level indicates FSIP1 promotes EMT and gastric cancer progression by regulating fibroblasts in tumor microenvironment
  218. Special Issue Advancements in oncology: bridging clinical and experimental research - Part I
  219. Ultrasound-guided transperineal vs transrectal prostate biopsy: A meta-analysis of diagnostic accuracy and complication rates
  220. Assessment of diagnostic value of unilateral systematic biopsy combined with targeted biopsy in detecting clinically significant prostate cancer
  221. SENP7 inhibits glioblastoma metastasis and invasion by dissociating SUMO2/3 binding to specific target proteins
  222. MARK1 suppress malignant progression of hepatocellular carcinoma and improves sorafenib resistance through negatively regulating POTEE
  223. Analysis of postoperative complications in bladder cancer patients
  224. Carboplatin combined with arsenic trioxide versus carboplatin combined with docetaxel treatment for LACC: A randomized, open-label, phase II clinical study
  225. Special Issue Exploring the biological mechanism of human diseases based on MultiOmics Technology - Part I
  226. Comprehensive pan-cancer investigation of carnosine dipeptidase 1 and its prospective prognostic significance in hepatocellular carcinoma
  227. Identification of signatures associated with microsatellite instability and immune characteristics to predict the prognostic risk of colon cancer
  228. Single-cell analysis identified key macrophage subpopulations associated with atherosclerosis
Downloaded on 25.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/med-2024-0994/html
Scroll to top button